168 related articles for article (PubMed ID: 23474960)
41. Diagnostic Performance of and Breast Tissue Changes at Early Breast MR Imaging Surveillance in Women after Breast Conservation Therapy.
Kim EJ; Kang BJ; Kim SH; Youn IK; Baek JE; Lee HS
Radiology; 2017 Sep; 284(3):656-666. PubMed ID: 28419815
[TBL] [Abstract][Full Text] [Related]
42. Diffusion-tensor MR imaging of the breast: hormonal regulation.
Nissan N; Furman-Haran E; Shapiro-Feinberg M; Grobgeld D; Degani H
Radiology; 2014 Jun; 271(3):672-80. PubMed ID: 24533873
[TBL] [Abstract][Full Text] [Related]
43. MR mammography: influence of menstrual cycle on the dynamic contrast enhancement of fibrocystic disease.
Rieber A; Nüssle K; Merkle E; Kreienberg R; Tomczak R; Brambs HJ
Eur Radiol; 1999; 9(6):1107-12. PubMed ID: 10415244
[TBL] [Abstract][Full Text] [Related]
44. Background Breast Parenchymal Signal During Menstrual Cycle on Diffusion-Weighted MRI: A Prospective Study in Healthy Premenopausal Women.
Kim YS; Yun B; Chu AJ; Lee SH; Shin HJ; Kim SM; Jang M; Shin SU; Moon WK
Korean J Radiol; 2024 Jun; 25(6):511-517. PubMed ID: 38807333
[TBL] [Abstract][Full Text] [Related]
45. Enhanced mass on contrast-enhanced breast MR imaging: Lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images.
Yabuuchi H; Matsuo Y; Okafuji T; Kamitani T; Soeda H; Setoguchi T; Sakai S; Hatakenaka M; Kubo M; Sadanaga N; Yamamoto H; Honda H
J Magn Reson Imaging; 2008 Nov; 28(5):1157-65. PubMed ID: 18972357
[TBL] [Abstract][Full Text] [Related]
46. Comparison between qualitative and quantitative assessment of background parenchymal enhancement on breast MRI.
Pujara AC; Mikheev A; Rusinek H; Gao Y; Chhor C; Pysarenko K; Rallapalli H; Walczyk J; Moccaldi M; Babb JS; Melsaether AN
J Magn Reson Imaging; 2018 Jun; 47(6):1685-1691. PubMed ID: 29140576
[TBL] [Abstract][Full Text] [Related]
47. A new quantitative image analysis method for improving breast cancer diagnosis using DCE-MRI examinations.
Yang Q; Li L; Zhang J; Shao G; Zheng B
Med Phys; 2015 Jan; 42(1):103-9. PubMed ID: 25563251
[TBL] [Abstract][Full Text] [Related]
48. Gadolinium-enhanced MR imaging of the liver: optimizing imaging delay for hepatic arterial and portal venous phases--a prospective randomized study in patients with chronic liver damage.
Kanematsu M; Semelka RC; Matsuo M; Kondo H; Enya M; Goshima S; Moriyama N; Hoshi H
Radiology; 2002 Nov; 225(2):407-15. PubMed ID: 12409573
[TBL] [Abstract][Full Text] [Related]
49. The lactating breast: contrast-enhanced MR imaging of normal tissue and cancer.
Espinosa LA; Daniel BL; Vidarsson L; Zakhour M; Ikeda DM; Herfkens RJ
Radiology; 2005 Nov; 237(2):429-36. PubMed ID: 16244250
[TBL] [Abstract][Full Text] [Related]
50. Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging.
Korobkin M; Lombardi TJ; Aisen AM; Francis IR; Quint LE; Dunnick NR; Londy F; Shapiro B; Gross MD; Thompson NW
Radiology; 1995 Nov; 197(2):411-8. PubMed ID: 7480685
[TBL] [Abstract][Full Text] [Related]
51. Non-mass-like enhancement on contrast-enhanced breast MR imaging: lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images.
Yabuuchi H; Matsuo Y; Kamitani T; Setoguchi T; Okafuji T; Soeda H; Sakai S; Hatakenaka M; Kubo M; Tokunaga E; Yamamoto H; Honda H
Eur J Radiol; 2010 Jul; 75(1):e126-32. PubMed ID: 19796900
[TBL] [Abstract][Full Text] [Related]
52. Endometriosis: Does the menstrual cycle affect magnetic resonance (MR) imaging evaluation?
Botterill EM; Esler SJ; McIlwaine KT; Jagasia N; Ellett L; Maher PJ; Yang N
Eur J Radiol; 2015 Nov; 84(11):2071-9. PubMed ID: 26283193
[TBL] [Abstract][Full Text] [Related]
53. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
54. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations.
Watanabe H; Kanematsu M; Goshima S; Kondo H; Onozuka M; Moriyama N; Bae KT
Radiology; 2011 Apr; 259(1):142-50. PubMed ID: 21248234
[TBL] [Abstract][Full Text] [Related]
55. The cisterna chyli: enhancement on delayed phase MR images after intravenous administration of gadolinium chelate.
Verma SK; Mitchell DG; Bergin D; Mehta R; Chopra S; Choi D
Radiology; 2007 Sep; 244(3):791-6. PubMed ID: 17652192
[TBL] [Abstract][Full Text] [Related]
56. The value of Gd-EOB-DTPA-enhanced MR imaging in characterizing cirrhotic nodules with atypical enhancement on Gd-DTPA-enhanced MR images.
Wang YC; Chou CT; Lin CP; Chen YL; Chen YF; Chen RC
PLoS One; 2017; 12(3):e0174594. PubMed ID: 28355258
[TBL] [Abstract][Full Text] [Related]
57. Ductal Carcinoma in Situ: Quantitative Preoperative Breast MR Imaging Features Associated with Recurrence after Treatment.
Luo J; Johnston BS; Kitsch AE; Hippe DS; Korde LA; Javid S; Lee JM; Peacock S; Lehman CD; Partridge SC; Rahbar H
Radiology; 2017 Dec; 285(3):788-797. PubMed ID: 28914599
[TBL] [Abstract][Full Text] [Related]
58. The value of contrast-enhanced dynamic and diffusion-weighted MR imaging for distinguishing benign and malignant splenic masses.
Choi SY; Kim SH; Jang KM; Kang TW; Song KD; Moon JY; Choi YH; Lee BR
Br J Radiol; 2016 Jul; 89(1063):20160054. PubMed ID: 27164031
[TBL] [Abstract][Full Text] [Related]
59. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
[TBL] [Abstract][Full Text] [Related]
60. Could parenchymal enhancement on contrast-enhanced spectral mammography (CESM) represent a new breast cancer risk factor? Correlation with known radiology risk factors.
Savaridas SL; Taylor DB; Gunawardana D; Phillips M
Clin Radiol; 2017 Dec; 72(12):1085.e1-1085.e9. PubMed ID: 28870431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
